Two-Year Results for MC1273, a Phase 2 Evaluation of Aggressive Dose De- Escalation for Adjuvant Chemoradiation in HPV+ Oropharynx Squamous Cell Carcinoma (OPSCC)Robert L. Foote, Javier García, Darlene E. Graner et al.|International Journal of Radiation Oncology*Biology*Physics|2017Cited by 16
Costs of Definitive Chemoradiation, Surgery, and Adjuvant Radiation Versus De-Escalated Adjuvant Radiation per MC1273 in HPV+ Cancer of the OropharynxMark R. Waddle, Robert C. Miller, J. Daniel et al.|International Journal of Radiation Oncology*Biology*Physics|2020Cited by 7
Cost Savings of Aggressive Dose De-Escalation for Adjuvant Chemoradiation in HPV+ Oropharynx Squamous Cell Carcinoma Versus Standard of Care; Cost Analysis of a Prospective Phase II StudyMark R. Waddle, Robert C. Miller, Sue L. Visscher et al.|International Journal of Radiation Oncology*Biology*Physics|2018Cited by 0